FdaNdcDirectoryPulse / compare
BRYTLY vs XTXFX WART REMOVER: FdaNdcDirectoryPulse comparison
BRYTLY (2026-10-16) and XTXFX WART REMOVER (2026-09-25) are peer FdaNdcDirectoryPulse records.
Data as of · Compiled by Zalwin from U.S. FDA National Drug Code (NDC) Directory via openFDA
Both records plus every comparable record, with all columns and source links · Card, Apple Pay, Google Pay or Link via Stripe
How does BRYTLY compare to XTXFX WART REMOVER?
| Field | BRYTLY | XTXFX WART REMOVER |
|---|---|---|
| Product | BRYTLY | XTXFX WART REMOVER |
| Generic name | Apraclonidine Hydrochloride | Salicylic Acid 45% |
| NDC | 0065-8596 | 87204-216 |
| Labeler | Alcon Laboratories, Inc. | Guangzhou Huixue Biotechnology Co., Ltd. |
| Product type | HUMAN OTC DRUG | HUMAN OTC DRUG |
| Approval pathway | NDA | OTC MONOGRAPH DRUG |
| Application number | NDA220341 | M028 |
| Dosage form | SOLUTION/ DROPS | LIQUID |
| Route | OPHTHALMIC | TOPICAL |
| Active ingredients | APRACLONIDINE HYDROCHLORIDE 1.25 mg/mL | SALICYLIC ACID .45 mg/30mL |
| Marketing start | 2026-10-16 | 2026-09-25 |
| Package configurations | 3 | 1 |
| Launch Signal Score | 45/100 | 15/100 |
| Peer rank and all 500 records (CSV) | 🔒 Click to unlock → | |
| Official source URLs for every peer record | 🔒 Click to unlock → | |
Official records: BRYTLY · XTXFX WART REMOVER
Get new listings in your categories
FdaNdcDirectoryPulse emails new drug listings matching your pathway and product type.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.